Abstract
1520
Objectives: Uterine sarcomas are rare mesenchymal aggressive tumors with a high rate of recurrence. This study assesses the role of FDG PET/CT in detecting recurrence and residual lesions in post-surgery patients. Materials and methods: Retrospectively analyzed 18 post-surgery FDG PET/CT scans of biopsy-proven uterine sarcoma patients, who underwent a scan to rule out suspected residual disease and suspected recurrence during follow-up. The images were evaluated by an experienced nuclear medicine physician as a single integrated imaging modality. Clinical follow-up (minimum 6 months), follow-up PET/CT, and histopathology were taken as the reference standard. Results: Out of 18 patients, 4 patients were lost to follow up. The final analysis was done on 14 patients. The median age of 14 studied patients was 48 years (range: 30-73 years). Histopathology was endometrial stromal sarcoma in 5 patients and leiomyosarcoma in 7 patients and undifferentiated uterine sarcoma in 2 patients. Out of 14 scans, 9 were positive and 5 were negative for a metabolically active lesion. Among the 9 positive scans,8 were true positive and 1 was false positive. All negative scans were true negative. Calculated the sensitivity as 100%(CI 67.56-100), specificity 83.33%(CI 43.65-96.99), positive predictive value 88.89%(CI 56.5-98.01), Negative predictive value 100% (CI 56.55-100). Conclusions: 18F-FDG PET/CT as a single integrated modality, is useful for post-surgery surveillance in uterine sarcoma patients.